Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in ICU
2020-001766-11Phase 2Completed
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of losartan and spironolactone in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Change in SOFA score at day 7. Started Apr 2020; status: completed.
02
Drugs
losartanspironolactone
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-001766-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001766-11.